Navigation Links
Varian Medical Systems to Exhibit X-Ray Tubes and Flat Panel Detector Technology Enhancements to Improve Digital Imaging at the ECR Annual Meeting
Date:2/29/2012

SALT LAKE CITY, Feb. 29, 2012 /PRNewswire/ -- ECR Booth #313/Expo C -- Varian Medical Systems, Inc.  (NYSE: VAR), will exhibit X-ray tubes and PaxScan® digital image detectors for fluoroscopy, angiography, cardiology and cone-beam CT imaging at the European Congress of Radiology (ECR) annual meeting in Vienna, Austria, from March 1- 5, 2012.   

"This year our exhibit reflects our dedication to continuous product improvement," said Stephen Kimmel, vice president of Sales and Marketing for Varian X-Ray Products.  "We've responded to the industry's need for advanced digital imaging solutions with revolutionary new designs of PaxPower™ X-ray tubes and a new generation of our PaxScan® line of image detectors designed to improve image quality and increase patient throughput."

The products to be highlighted at ECR are:

  • PaxScan® 1515DX – a mid-size CBCT and panoramic imaging panel using Varian's new DX technology, a proprietary, state of the art 6th generation architecture, featuring increased frame rates, improved low dose imaging and 16-bit data acquisition.  The panel is suitable for use in mini C-arm applications and is also well suited for dental and industrial applications.   
  • PaxScan® 4336X – a cassette sized flat panel detector designed with low noise electronics, 2.8 second acquisition time, internal shock event recorder and weighing only 3.1kg. The detector has 16-bit data acquisition and is available with or without handles.  
  • PaxScan® 4343CB  - a flat panel detector developed for applications in R&F, surgical, ENT, oncology and orthopedics.  The large field of view panel features multiple sensitivity ranges, extended dynamic range modes and a 139 µm pixel size for high quality radiography. 
  • PaxPower™ FP 2250 - an X-ray tube optimized for high throughput interventional procedures on systems including portable surgical CT.  The compact tube platforms were designed with higher heat dissipation which allows for higher patient throughput.
  • PaxPower™ M-1500 - Varian's first X-ray tube developed specifically for advanced mammography applications such as tomosynthesis and CT.  The M-1500 provides exceptional performance in a space efficient design allowing high quality imaging in the chest wall region.  

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications.  Varian Medical Systems employs approximately 5,900 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com or follow us on Twitter.

FOR INFORMATION CONTACT:
Elaine Rebele, Varian Medical Systems
801-978-5715   elaine.rebele@varian.com


'/>"/>
SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Research and Markets has announced the addition of the ... to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Fibromyalgia ...
(Date:2/23/2017)... Regulus Therapeutics Inc . (Nasdaq: RGLS), ... innovative medicines targeting microRNAs, today announced it will release ... Thursday, March 2, 2017 after the market closes. ... on March 2, 2017 at 5:00 p.m. Eastern Time ... results and provide a general business update.  A live ...
(Date:2/23/2017)... 23, 2017 According to a ... (X-ray Imaging Digital, Analog), MRI (Closed, Open), Ultrasound, CT, ... Oncology), End User (Hospitals, Imaging Centers) - Global Forecast ... global market over the forecast period of 2016 to ... Billion by 2021, at a CAGR of 6.6% from ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) ... company later this year. Dyer started as the Chairman of the Management Committee ... establishment of the corporation including the recruitment of investor/owners and development of the business ...
(Date:2/23/2017)... TX (PRWEB) , ... February 23, 2017 , ... ... announced an official 2017 partnership with The Jensie Gran Fondo of Marin. For ... and UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & Analytics® (HRA®) ... fight against cancer, has produced a seminal study that asked cancer survivors and ... findings in a webinar, Defining Compassionate Care Through the Voices of Patients and ...
Breaking Medicine News(10 mins):